Cumberland Pharma $100M Apotex Deal

Cumberland Pharmaceuticals shares jumped about 80% after announcing a $100 million cash deal with an Apotex affiliate to sell its branded drug line.
The transaction, pending shareholder approval, lets Cumberland retain its pipeline and majority stake in Cumberland Emerging Technologies Inc.
CEO A.J. Kazimi said the deal unlocks shareholder value and lets the company focus on orphan‑drug candidates like ifetroban.
Ifetroban has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations and showed breakthrough Phase II results in Duchenne cardiomyopathy.